Command Palette

Search for a command to run...

Clinical Trials · NCT02721888

Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism

TerminatedPhase 4Liraglutide (Prohibited)
Phase
Phase 4
Recruitment status
Terminated
Sponsor
Centre Hospitalier Universitaire Dijon
Enrollment
127
Start date
Jul 2012
Locations
1 site, France
Primary endpoint
Effect of liraglutide on fatty liver content evaluated by proton-spectroscopy (1H-spectroscopy and lipoprotein kinetics, in patients with type 2 diabetes
View Liraglutide compound reference